Natural product-derived Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Artemisinin, isolated from Artemisia Annua L, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signalling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 27/July/2017, 1.00 pm

Molecular therapy for glioblastoma: MiRNA-340  inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 27/July/2017,  12.54 am
July 26, 2017
Natural product-derived therapy for brain tumor and oesophageal squamous cell carcinoma:  Matrine, isolated from Sophora flavescens, inhibits the expression of Integrin a7 (ITGA7), impairs laminin-induced/FAK mediated signalling, inhibits the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 27/July/2017, 10.30 pm
July 27, 2017
Show all

Introduction:What they say:

A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA; and Division of Pediatric Hematology and Oncology, Children’s Hospital, Boston, Massachusetts 02115, USA has identified Ptpn2 as a cancer immunotherapy target. This study was published, in the July 2017 issue of Nature (one of the best journals in General science with an impact factor of 43 plus), by Prof Haining WN, Manguso and others


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Artemisinin, isolated from Artemisia Annua L, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signalling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene


From Significance of the study to Public health relevance: 

Given that: (i) PD-1 checkpoint blockade is effective only in minority of cancer patients; (ii) each year nearly 14 million people are diagnosed with cancer globally; (iii) cancer deaths globally are expected to be doubled in the next decade; (iv) metastasis is the principle reason for most of the cancer deaths; (v) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to activate patients’ immune system against tumors (Cancer immunotherapy); (ii) a way to improve the efficacy of immunotherapy by targeting a number of immune evasion molecules simultaneously; (iii) anti-cancer drugs that target cancer stem cells that aid in tumor relapse and resistance; (iv) anti-cancer drugs that target cell adhesion molecules that aid in metastatic spread; (v) a cheaper alternative to the existing expensive anticancer drugs; (vi) a side-effect-free natural product-based drug; (vii) increase the therapeutic index of anti-cancer drugs; and (viii) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


What is known?

It has recently been shown that blocking immune evasion molecules, including cell surface receptor PD-1, with antibodies, one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity:

This study suggests a natural product-based therapy for enhancing the efficacy of cancer immunotherapy.

The antimalarial drug Artemisinin, discovered by Chinese chemist-cum-Professor Tu Youyu, for which she shared the Noble prize with Profs. William C. Campbell, Satoshi Omura in 2015, has also been shown to function as an anti-cancer agent. However, the detailed mechanistic insights is yet to emerge.

Artemisinin, by increasing the expression of its target gene, it may decrease PTPN2/TC-PTP expression. Thereby, it may: (i) diminish the expression of a number of immune evasion molecules in cancer cells; (ii) increase IFNγ signaling; (iii) increase antigen presentation; (iv) augment unfolded protein response: (v) increase the number of tumor-infiltrating immune cells; (vi) augment T-cell anti-tumor immunity; (vii) decrease tumor burden and promote growth suppression; (viii) increase survival of patients with cancers; and (ix) increase the efficacy of immunotherapy (fig. 1).

Figure1. Mechanistic insights into how Artemisinin enhances the efficacy of Cancer Immunotherapy. Artemisinin, by increasing the expression of its target genes, it promotes the expression of a number of tumor suppressor genes, inhibits the expression of a number of immune invasion molecules, including PTPN2//TC-PTP, augments T-cell mediated anti-tumor immunity and attenuates tumor growth

Thus, pharmacological formulations encompassing “Artemisinin or its analogues, either alone or in combination with any of the known anticancer agents“ may be used to (i) inhibit the progression of tumors; and (ii) enhance the efficacy of Cancer immunotherapy. [easy_payment currency=”USD”]

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $750#

Undisclosed mechanistic information: How Artemisinin suppresses the expression of PTPN2/TC-PTP and augments anti-tumor immunity

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Citation: Boominathan, L., Natural product-derived Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Artemisinin, isolated from Artemisia Annua L, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signalling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 27/July/2017, 1.00 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

 

 

 

Comments are closed.